Statins to treat multiple sclerosis: Friend or foe?

Neurology

Volumn 71, Issue 18, 2008, Pages 1386-1387

  Goldman, Myla D ^a   Cohen, Jeffrey A ^b  

^a UNIVERSITY OF VIRGINIA   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; BETA1A INTERFERON; GADOLINIUM; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO;

CLINICAL TRIAL; EDITORIAL; HUMAN; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PILOT STUDY; PRIORITY JOURNAL; RELAPSE; RISK ASSESSMENT; TREATMENT DURATION; NOTE;

HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MULTIPLE SCLEROSIS;

EID: 58149238092     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/01.wnl.0000327876.72639.e7     Document Type: Editorial

References (12)

1. Youssef S, Stuve O, Patarroyo JC, et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 2002;420:78-84.
2. Neuhaus O, Strasser-Fuchs S, Fazekas F, et al. Statins as immunomodulators: comparison with interferon-β1b in MS. Neurology 2002;59:990-997.
3. Paul F, Waiczies S, Wuerfel J, et al. Oral high-dose atar-vastatin treatment in relapsing-remitting multiple sclerosis. PLoS ONE 2008;3:e1928.
4. Vollmer T, Key L, Durkalski V, et al. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 2004;363:1607-1608.
5. Birnbaum G, Cree B, Altafullah I, Zinser M, Reder AT. Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis. Neurology 2008;71: 1390-1395.
6. Markovic-Plese S, Speer D, Jin J, Smrtka J, Ingram L, Jewells V. Statin and intramuscular interferon beta-1a combination therapy is safe and well tolerated in patients with clinically isolated syndrome suggestive of multiple sclerosis, a pilot study. Mult Scler 2007;13: S270. Abstract.
7. Orefice G, Quarantelli M, Salvatore P, et al. An open label randomised clinical trial of atorvastatin in combination with IFN beta-1a in active MS patients: 12 months results. Mult Scler 2007;13:S56-S57. Abstract.
8. Rudick R, Pace A, Panzara M, et al. Effects of statins on intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis. Mult Scler 2007;13:S57. Abstract.
9. Sorensen PS, Frederiksen JL, Lycke J, Sellebjerg F. Does simvastatin antagonise the effect of interferon beta? Interim safety analysis of the ongoing SIMCOMBIN study. Mult Scler 2007;13:S25. Abstract.
10. Kieseier BC, Archelos JJ, Hartung HP. Different effects of simvastatin and interferon beta on the proteolytic activity of matrix metalloproteinases. Arch Neurol 2004;61:929-932.
11. Ioannidis JPA. Why most published research findings are false. PloS Medicine 2005;2:e124.
12. Marrie RA. PhD Thesis: The influence of comorbid diseases and health behaviors on clinical characteristics, disability at diagnosis, and disability progression in multiple sclerosis. Epidemiology and Biostatistics, Case Western Reserve University, 2007.